B-ALL cells resistant to CD19-targeted treatment were several-fold more sensitive to the growth inhibitory effects of small-molecule inhibitors against BTK and downstream MEK than were parental B-ALL cells. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.